Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) FCF Margin (2016 - 2025)

Cytosorbents' FCF Margin history spans 15 years, with the latest figure at 53.42% for Q4 2025.

  • Quarterly results put FCF Margin at 53.42% for Q4 2025, down 3010.0% from a year ago — trailing twelve months through Dec 2025 was 33.84% (up 672.0% YoY), and the annual figure for FY2025 was 33.84%, up 672.0%.
  • FCF Margin for Q4 2025 was 53.42% at Cytosorbents, down from 27.35% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 13.37% in Q2 2021 to a low of 101.59% in Q1 2022.
  • The 5-year median for FCF Margin is 53.83% (2025), against an average of 52.14%.
  • The sharpest move saw FCF Margin tumbled -7561bps in 2022, then soared 6330bps in 2023.
  • Year by year, FCF Margin stood at 84.7% in 2021, then skyrocketed by 32bps to 57.71% in 2022, then dropped by -30bps to 75.02% in 2023, then soared by 69bps to 23.32% in 2024, then crashed by -129bps to 53.42% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 53.42%, 27.35%, and 16.09% for Q4 2025, Q3 2025, and Q2 2025 respectively.